Navigation Links
Biopharmaceutical infrastructure key to lower drug development costs
Date:10/11/2007

Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study* sponsored by the National Institute of Standards and Technology (NIST).

Prepared by RTI International for NIST, the studys authors found that over the last two decades emphasis in new drug development has shifted from small-molecule chemicals to large-molecule proteins and other biopharmaceuticals such as human insulin, gene therapies and specialized antibiotic treatments. The report notes that the biopharmaceutical industry currently spends about $21 billion annually on research and development and has commercialized over 400 products.

Producing and maintaining the infrastructure that supports R&D, manufacturing and postmarket surveillance, including core data, methods, and standards used to determine the quality and efficacy of biopharmaceuticals, costs the industry a total of $1.2 billion annually, according to the report. The study focused on expenditures for four major categories of technical infrastructure: bioimaging, biomarkers, bioinformatics, and gene expression, as well as expenditures for infrastructure supporting processing and quality control for commercial manufacturing and activities involved with postmarket surveilliance. (See chart.)

According to the study, improvements to this infrastructure, such as better standardization of data collection and analysis, would be expected to save between 25 and 48 percent of R&D expenses for each new biopharmaceutical drug approved by the Food and Drug Administration. Better technical infrastructure is also projected to reduce the average development time per approved drug from 122 months to 98 months, a reduction of 20 percent. The study further estimated that total industry manufacturing costs could be reduced over the four major phases of manufacturing by $1.5 bil
'/>"/>

Contact: Gail Porter
gail.porter@nist.gov
301-975-3392
National Institute of Standards and Technology (NIST)
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
2. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
3. Medical whistleblowers speak out
4. The evolutionary triumph of flower power
5. Bumblebees copy one another when contending with unfamiliar flowers
6. Analysis of flower genes reveals the fate of an ancient gene duplication
7. Gene therapy to lower blood pressure just enough
8. Long-sought flower-inducing molecule found
9. FDA: Highly Unlikely Green Tea Lowers Cancer Risk
10. Divergent mating systems and parental conflict as a barrier to hybridization in flowering plants
11. Reducing antibiotic use lowers rates of drug-resistant bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... release is available in German . ... has substantially increased around the world. As a team of ... Technical University of Dresden and the University of Freiburg headed ... temporal trends of global pollination benefit" in the open-access journal ...
... - Researchers at the Centre for Addiction and Mental Health ... form of intellectual disability, as well as how it likely ... Scientist Dr. John Vincent and his team found a mutation ... a finding to be published in the May issue of ...
... successful in attracting funding of an Alexander von Humboldt ... response to an application to appoint Professor Dr. Wolfram ... the USA, to the Center for Thrombosis and Hemostasis ... announced jointly by the Alexander von Humboldt Foundation and ...
Cached Biology News:Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3New form of intellectual disability discovered 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 3
(Date:4/1/2015)... TORONTO , April 1, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), is pleased to announce that ... holds 54% equity, has entered into an agreement ... Biohaven,s first clinical trial with their lead compound ... the identification and development of clinical stage neuroscience ...
(Date:4/1/2015)... 2014 /CNW/ - Canada,s Research-Based Pharmaceutical ... newly released report on Cost Drivers of Public Drug Plans ... to the report, the rates of change in drug costs ... of -0.8 percent in 2012/13 for a number of select ... examines the costs of medicines without considering their overall impact ...
(Date:4/1/2015)... Los Angeles, CA (PRWEB) April 01, 2015 ... portable reader that can read both chromatographic and fluorescent ... a leading supplier of high performance, quantitative readers and ... readers globally. The HRDR-400 is a first of its ... capabilities in one instrument. , Dr. Neven Karlovac, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 National recruitment ... the placement of Brad Allen as Head of Sales ... the health system market. , Allen brings over ... and sales at a number of companies including Dell ... knowledge and experience were a perfect fit for accomplishing ...
Breaking Biology Technology:Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Slone Partners Fills Head of Sales at Optimal Medicine 2
... , , , , , , ... CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... its financial results for,the third quarter of its 2010 fiscal year, ... Third Quarter 2010 Highlights, -- Net sales increased ...
... , NEW YORK , Feb. 10 ... Board: ILNS), a biopharmaceutical company focused on development of ... that several of its significant shareholders (the "Interested Shareholders") ... the Company and assist the Company in its efforts ...
... , SILVER SPRING, Md. , and ... a wholly-owned subsidiary of United Therapeutics Corporation (Nasdaq: UTHR ... Agreement with ImmuneWorks, Inc. to pursue development of ImmuneWorks, lead ... for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Primary ...
Cached Biology Technology:China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 11China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 12China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 13Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
Biology Products: